AR119761A2 - Benzamidas sustituidas con 1,3-tiazol-2-ilo - Google Patents
Benzamidas sustituidas con 1,3-tiazol-2-iloInfo
- Publication number
- AR119761A2 AR119761A2 ARP200102296A ARP200102296A AR119761A2 AR 119761 A2 AR119761 A2 AR 119761A2 AR P200102296 A ARP200102296 A AR P200102296A AR P200102296 A ARP200102296 A AR P200102296A AR 119761 A2 AR119761 A2 AR 119761A2
- Authority
- AR
- Argentina
- Prior art keywords
- thiazol
- substituted benzamides
- alkyl
- substituted
- racemate
- Prior art date
Links
- -1 1,3-THIAZOL-2-YL Chemical group 0.000 title 1
- 229940054066 benzamide antipsychotics Drugs 0.000 title 1
- 150000003936 benzamides Chemical class 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula general (1), caracterizado porque R¹ representa C₁₋₄-alquilo; R² representa -(CH₂)q-morfolinilo sustituido con Rᶜ; R³ representa C₁₋₄-alquilo; Rᶜ representa metilo; A representa CF₃-pirimidinilo; q representa el número entero 1; o un enantiómero, diastereómero, racemato, hidrato, solvato, o una sal del mismo, o una mezcla de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196954 | 2014-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119761A2 true AR119761A2 (es) | 2022-01-12 |
Family
ID=52015966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104007A AR102948A1 (es) | 2014-12-09 | 2015-12-09 | Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3 |
| ARP200102296A AR119761A2 (es) | 2014-12-09 | 2020-08-13 | Benzamidas sustituidas con 1,3-tiazol-2-ilo |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150104007A AR102948A1 (es) | 2014-12-09 | 2015-12-09 | Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3 |
Country Status (42)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3587417T (pt) | 2014-12-09 | 2022-03-16 | Bayer Ag | Benzamidas substituídas por 1,3-tiazol-2-ilo |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN106588785A (zh) * | 2016-12-02 | 2017-04-26 | 山东吉田香料股份有限公司 | 一种乙酰基吡嗪的制备方法 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| KR20210008070A (ko) * | 2018-05-15 | 2021-01-20 | 바이엘 악티엔게젤샤프트 | 신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드 |
| AU2019269049A1 (en) * | 2018-05-15 | 2020-11-26 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| AU2019353424B2 (en) | 2018-10-05 | 2022-12-08 | Shionogi & Co., Ltd. | Medicine for treating chronic cough |
| US20210346391A1 (en) * | 2018-10-10 | 2021-11-11 | Bellus Health Cough Inc. | Treatment of pruritus with p2x3 modulators |
| JP7578602B2 (ja) | 2019-02-25 | 2024-11-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | Ｐ２ｘ３修飾薬での治療 |
| MX2021012162A (es) * | 2019-04-05 | 2021-11-03 | Syngenta Crop Protection Ag | Compuestos de diazina-amida activos como pesticidas. |
| PE20220172A1 (es) * | 2019-04-11 | 2022-01-28 | Syngenta Crop Protection Ag | Compuestos de diazina-amida activos como pesticidas |
| WO2020239953A1 (en) | 2019-05-31 | 2020-12-03 | Chiesi Farmaceutici S.P.A. | Pyridopyrimidines derivatives as p2x3 inhibitors |
| AU2020285336A1 (en) | 2019-05-31 | 2022-01-06 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as P2X3 inhibitors |
| EP3757103A1 (en) | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
| CN113082023B (zh) * | 2019-12-23 | 2024-03-01 | 武汉朗来科技发展有限公司 | P2x3抑制剂和p2x4抑制剂的药物组合及其应用 |
| WO2021238834A1 (zh) * | 2020-05-25 | 2021-12-02 | 中国医药研究开发中心有限公司 | 芳甲酰胺类化合物及其制备方法和医药用途 |
| WO2022063205A1 (zh) * | 2020-09-24 | 2022-03-31 | 中国医药研究开发中心有限公司 | 芳基甲酰胺类化合物及其制备方法和医药用途 |
| CN114315818A (zh) * | 2020-09-30 | 2022-04-12 | 武汉人福创新药物研发中心有限公司 | 苯甲酰胺类化合物及其用途 |
| MX2023005805A (es) | 2020-11-27 | 2023-06-01 | Chiesi Farm Spa | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). |
| CA3196333A1 (en) | 2020-11-27 | 2022-06-02 | Claudio FIORELLI | Amino quinazoline derivatives as p2x3 inhibitors |
| EP4251273B1 (en) | 2020-11-27 | 2025-03-12 | Chiesi Farmaceutici S.p.A. | Phthalazine derivatives as p2x3 inhibitors |
| CN114591317A (zh) * | 2020-12-04 | 2022-06-07 | 武汉人福创新药物研发中心有限公司 | P2x3抑制剂及其用途 |
| WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
| WO2022253943A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide |
| CN116396285A (zh) * | 2022-01-04 | 2023-07-07 | 上海华汇拓医药科技有限公司 | 氘代四氢呋喃类化合物制备及其应用 |
| US12024285B1 (en) | 2022-03-10 | 2024-07-02 | Skypad Tech, Inc. | Modular mobility system including thrusters movably connected to a support structure |
| JP2025510348A (ja) | 2022-03-29 | 2025-04-14 | 人福医薬集団股▲分▼公司 | Ｐ２ｘ３阻害剤化合物及びその塩、結晶多形並びに使用 |
| WO2024131948A1 (zh) * | 2022-12-22 | 2024-06-27 | 人福医药集团股份公司 | 制备p2x3抑制剂的方法 |
| AR132737A1 (es) | 2023-05-22 | 2025-07-23 | Chiesi Farm Spa | Proceso e intermedios para la preparación de un inhibidor p2x3 |
| CN117777048B (zh) * | 2023-09-25 | 2024-09-20 | 上海科利生物医药有限公司 | 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法 |
| WO2025140586A1 (zh) * | 2023-12-29 | 2025-07-03 | 人福医药集团股份公司 | 一种p2x3受体拮抗剂的固体分散体及其制备工艺 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1885369B1 (en) | 2005-05-04 | 2015-09-23 | Evotec AG | Fused heterocyclic compounds, and compositions and uses thereof |
| CN103159692B (zh) | 2006-06-29 | 2015-03-18 | 弗·哈夫曼-拉罗切有限公司 | 四唑取代的芳基酰胺类 |
| US8501933B2 (en) * | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
| CN101528717B (zh) | 2006-11-09 | 2013-04-24 | 弗·哈夫曼-拉罗切有限公司 | 噻唑和*唑-取代的芳基酰胺类化合物 |
| CA2682162C (en) | 2007-04-02 | 2016-05-10 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| PT2139334E (pt) | 2007-04-17 | 2013-10-02 | Evotec Ag | Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| US20090317360A1 (en) * | 2007-06-12 | 2009-12-24 | Genelabs Technologies, Inc. | Anti-viral inhibitors and methods of use |
| WO2009058298A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3, receptor antagonists for treatment of pain |
| CA2703915C (en) | 2007-10-31 | 2015-02-24 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
| KR101405746B1 (ko) | 2007-12-17 | 2014-06-10 | 에프. 호프만-라 로슈 아게 | 트리아졸 치환된 아릴아미드 유도체 및 ｐ２ｘ３ 및/또는 ｐ２ｘ２／３ 퓨린성 수용체 길항제로서의 용도 |
| EP2234981B1 (en) | 2007-12-17 | 2016-03-30 | F. Hoffmann-La Roche AG | Novel imidazole-substituted arylamides |
| ES2517518T3 (es) | 2007-12-17 | 2014-11-03 | F. Hoffmann-La Roche Ag | Derivados arilamida sustituidos con tetrazol y su utilización como antagonistas de receptores purinérgicos P2X3 y/o P2X2/3 |
| CA2707988C (en) | 2007-12-17 | 2016-08-30 | F. Hoffmann-La Roche Ag | Novel pyrazole-substituted arylamides |
| JP5539235B2 (ja) * | 2008-02-29 | 2014-07-02 | エボテック・アーゲー | アミド化合物、組成物およびそれらの使用 |
| JP5608655B2 (ja) | 2008-09-18 | 2014-10-15 | エヴォテック アーゲー | Ｐ２ｘ３受容体活性のモジュレーター |
| CN102271682B (zh) * | 2008-10-31 | 2015-12-16 | 默沙东公司 | 用于治疗疼痛的p2x3受体拮抗剂 |
| AU2009328347B2 (en) | 2008-12-16 | 2016-06-09 | F. Hoffmann-La Roche Ag | Thiadiazole-substituted arylamides |
| CA2754654A1 (en) | 2009-06-22 | 2010-12-29 | F. Hoffmann-La Roche Ag | Novel oxazolone and pyrrolidinone-substituted arylamides |
| ES2450891T3 (es) | 2009-06-22 | 2014-03-25 | F. Hoffmann-La Roche Ag | Bifenilamidas útiles como moduladores de receptores P2X3 y/o P2X2/3 |
| EP2533783B8 (en) | 2010-01-13 | 2015-12-16 | Tempero Pharmaceuticals, Inc. | COMPOUNDS AND METHODS for the inhibition of HDAC |
| WO2013009810A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| US9562041B2 (en) * | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| JP6254169B2 (ja) | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
| CN105246888B (zh) | 2013-01-31 | 2017-09-05 | 尼奥迈德研究所 | 咪唑并吡啶化合物及其用途 |
| PT3587417T (pt) * | 2014-12-09 | 2022-03-16 | Bayer Ag | Benzamidas substituídas por 1,3-tiazol-2-ilo |
| US10183937B2 (en) * | 2014-12-09 | 2019-01-22 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides |
| KR20210008070A (ko) | 2018-05-15 | 2021-01-20 | 바이엘 악티엔게젤샤프트 | 신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드 |
| AU2019269049A1 (en) | 2018-05-15 | 2020-11-26 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| EP3757103A1 (en) | 2019-06-27 | 2020-12-30 | Bayer AG | Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases |
-
2015
- 2015-12-07 PT PT191817105T patent/PT3587417T/pt unknown
- 2015-12-07 KR KR1020237021217A patent/KR20230098368A/ko not_active Withdrawn
- 2015-12-07 WO PCT/EP2015/078765 patent/WO2016091776A1/en not_active Ceased
- 2015-12-07 LT LTEP19181710.5T patent/LT3587417T/lt unknown
- 2015-12-07 EA EA201791261A patent/EA032312B1/ru not_active IP Right Cessation
- 2015-12-07 US US15/534,855 patent/US10174016B2/en active Active
- 2015-12-07 CR CR20170242A patent/CR20170242A/es unknown
- 2015-12-07 RS RS20220250A patent/RS63014B1/sr unknown
- 2015-12-07 CN CN201910653985.0A patent/CN110256418B/zh not_active Expired - Fee Related
- 2015-12-07 RS RS20211014A patent/RS62227B1/sr unknown
- 2015-12-07 SI SI201531781T patent/SI3587417T1/sl unknown
- 2015-12-07 MA MA50674A patent/MA50674B1/fr unknown
- 2015-12-07 HU HUE19181710A patent/HUE058009T2/hu unknown
- 2015-12-07 DK DK19181710.5T patent/DK3587417T3/da active
- 2015-12-07 SG SG11201704717VA patent/SG11201704717VA/en unknown
- 2015-12-07 NZ NZ761161A patent/NZ761161A/en unknown
- 2015-12-07 EP EP19181710.5A patent/EP3587417B9/en active Active
- 2015-12-07 EP EP15804824.9A patent/EP3230281B1/en active Active
- 2015-12-07 SI SI201531643T patent/SI3230281T1/sl unknown
- 2015-12-07 EA EA201891120A patent/EA034273B1/ru not_active IP Right Cessation
- 2015-12-07 SG SG10202012274RA patent/SG10202012274RA/en unknown
- 2015-12-07 PL PL19181710T patent/PL3587417T3/pl unknown
- 2015-12-07 PE PE2017000984A patent/PE20180227A1/es unknown
- 2015-12-07 MY MYPI2017702127A patent/MY192690A/en unknown
- 2015-12-07 MX MX2020005909A patent/MX387478B/es unknown
- 2015-12-07 AU AU2015359626A patent/AU2015359626B2/en not_active Ceased
- 2015-12-07 HR HRP20220371TT patent/HRP20220371T1/hr unknown
- 2015-12-07 JO JOP/2015/0301A patent/JOP20150301B1/ar active
- 2015-12-07 ES ES15804824T patent/ES2882952T3/es active Active
- 2015-12-07 LT LTEP15804824.9T patent/LT3230281T/lt unknown
- 2015-12-07 PL PL15804824T patent/PL3230281T3/pl unknown
- 2015-12-07 MA MA41135A patent/MA41135B1/fr unknown
- 2015-12-07 CA CA2969952A patent/CA2969952A1/en active Pending
- 2015-12-07 KR KR1020177018575A patent/KR102548799B1/ko active Active
- 2015-12-07 UA UAA201707107A patent/UA120382C2/uk unknown
- 2015-12-07 ES ES19181710T patent/ES2908822T3/es active Active
- 2015-12-07 CU CU2017000077A patent/CU24411B1/es unknown
- 2015-12-07 CR CR20210108A patent/CR20210108A/es unknown
- 2015-12-07 UY UY0001036422A patent/UY36422A/es active IP Right Grant
- 2015-12-07 BR BR112017012327-4A patent/BR112017012327B1/pt not_active IP Right Cessation
- 2015-12-07 PT PT158048249T patent/PT3230281T/pt unknown
- 2015-12-07 MX MX2017007658A patent/MX377651B/es active IP Right Grant
- 2015-12-07 CN CN201580075714.1A patent/CN107207507B/zh not_active Expired - Fee Related
- 2015-12-07 DK DK15804824.9T patent/DK3230281T3/da active
- 2015-12-07 HR HRP20211002TT patent/HRP20211002T1/hr unknown
- 2015-12-07 JP JP2017530625A patent/JP6544665B2/ja not_active Expired - Fee Related
- 2015-12-07 PE PE2021001723A patent/PE20220253A1/es unknown
- 2015-12-07 TN TN2017000244A patent/TN2017000244A1/en unknown
- 2015-12-07 HU HUE15804824A patent/HUE055290T2/hu unknown
- 2015-12-08 TW TW104141168A patent/TWI716371B/zh not_active IP Right Cessation
- 2015-12-08 TW TW110100512A patent/TWI780562B/zh not_active IP Right Cessation
- 2015-12-09 AR ARP150104007A patent/AR102948A1/es unknown
-
2017
- 2017-06-05 IL IL25266517A patent/IL252665B/en active IP Right Grant
- 2017-06-08 PH PH12017501079A patent/PH12017501079A1/en unknown
- 2017-06-09 DO DO2017000137A patent/DOP2017000137A/es unknown
- 2017-06-09 CO CONC2017/0005742A patent/CO2017005742A2/es unknown
- 2017-06-09 SV SV2017005461A patent/SV2017005461A/es unknown
- 2017-06-09 NI NI201700073A patent/NI201700073A/es unknown
- 2017-06-09 CL CL2017001488A patent/CL2017001488A1/es unknown
- 2017-06-09 EC ECIEPI201736253A patent/ECSP17036253A/es unknown
- 2017-11-21 US US15/820,429 patent/US10202369B2/en active Active
-
2018
- 2018-08-08 DO DO2018000182A patent/DOP2018000182A/es unknown
- 2018-11-13 JP JP2018212898A patent/JP6647371B2/ja not_active Expired - Fee Related
- 2018-11-15 US US16/192,314 patent/US10472354B2/en active Active
-
2019
- 2019-09-19 IL IL269468A patent/IL269468B/en active IP Right Grant
- 2019-09-19 IL IL269467A patent/IL269467B/en active IP Right Grant
- 2019-09-25 IL IL269661A patent/IL269661B/en active IP Right Grant
- 2019-10-01 US US16/589,838 patent/US11142523B2/en not_active Expired - Fee Related
-
2020
- 2020-06-07 IL IL275183A patent/IL275183B/en active IP Right Grant
- 2020-08-13 AR ARP200102296A patent/AR119761A2/es not_active Application Discontinuation
-
2021
- 2021-06-14 IL IL283979A patent/IL283979B/en unknown
- 2021-08-20 CY CY20211100750T patent/CY1124486T1/el unknown
- 2021-09-09 US US17/470,459 patent/US20230053411A1/en not_active Abandoned
-
2022
- 2022-03-15 CY CY20221100217T patent/CY1125083T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119761A2 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| AR101995A1 (es) | COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6 | |
| DK3728252T3 (da) | 4-azaindolforbindelser | |
| EP3801527A4 (en) | Novel methods | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| PL3245744T3 (pl) | Sygnalizowanie ograniczenia podzbioru książki kodowej | |
| DK3774862T3 (da) | Nye GLP-1-analoger | |
| EP3423435A4 (en) | SUBSTITUTED INDOL-MCL-1 INHIBITORS | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| ECSP17054980A (es) | Inhibidores selectivos de bace1 | |
| AR098274A1 (es) | Inhibidor de grelina o-acil transferasa | |
| DK3587705T3 (da) | Lodret forskalling | |
| AR095523A1 (es) | Derivados piridin-4-ilo | |
| EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
| MX387796B (es) | Compuestos de aminocarbonilcarbamato. | |
| EP3662622C0 (en) | SUPPORT FOR REPORTING AN ENVELOPE | |
| EA201691924A1 (ru) | Фармацевтические композиции | |
| CY1123408T1 (el) | Φαρμακευτικες συνθεσεις και χρηση των αυτων | |
| IL282753A (en) | Immunogenic composition | |
| EP3701997A4 (en) | HIGH DENSITY MICRON NEEDLE | |
| AR107163A1 (es) | Inhibidores de quinasa | |
| EP4029505C0 (en) | INJECTION CONTAINING P-BORONOPHENYLALANINE | |
| EP3774621A4 (en) | Media catchers | |
| DOP2017000016A (es) | Nueva sal de disoproxilo de tenofovir | |
| AR105955A1 (es) | Método para producir una piridinacarboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |